- Conditions
- Vomiting, Nausea, Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Casopitant (GW679769) oral tablets, Casopitant (GW679769) intravenous, Dexamethasone intravenous, Ondansetron oral tablets, placebo
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,840 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 86
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Fayetteville, Arkansas + 78 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 89
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Neoplasms, Chemotherapy-induced Nausea and Vomiting
- Interventions
- eSSET-CINV
- Other
- Lead sponsor
- University of Central Florida
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Palonosetron HCl Buccal Film 0.5 mg, IV Palonosetron 0.25 mg
- Drug
- Lead sponsor
- Xiamen LP Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 328 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 13
- States / cities
- Chandler, Arizona • Anaheim, California • Lakeland, Florida + 9 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- GRANISETRON EXTENDED RELEASE INJECTION (GERSC)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Fosaprepitant Dimeglumine, 5-HT3 antagonist, Dexamethasone
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 6 Months to 17 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 5
- States / cities
- Phoenix, Arizona • Los Angeles, California • Chicago, Illinois + 2 more
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant - Oral, Rolapitant - IV
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chemotherapy Induced Nausea and Vomiting
- Interventions
- dronabinol, ondansetron, dronabinol/ondansetron, placebo
- Drug
- Lead sponsor
- Solvay Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 64 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2004
- U.S. locations
- 43
- States / cities
- Tucson, Arizona • Anaheim, California • Fountain Valley, California + 37 more
- Conditions
- Extrahepatic Bile Duct Cancer, Nausea, Vomiting, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
- Interventions
- aprepitant, gemcitabine hydrochloride, capecitabine, fluorouracil, radiation therapy, questionnaire administration, quality-of-life assessment, nausea and vomiting therapy, management of therapy complications
- Drug · Procedure · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2012
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
- Conditions
- Nausea, Vomiting
- Interventions
- Peppermint Essential Oil, Ginger Essential Oil, or Pure Vanilla Extract
- Other
- Lead sponsor
- Milton S. Hershey Medical Center
- Other
- Eligibility
- 21 Years to 89 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Hershey, Pennsylvania
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Palonosetron, ondansetron, Dexamethasone
- Drug
- Lead sponsor
- Northside Hospital, Inc.
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 85 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Oral GW679769, IV Cyclophosphamide 500-700mg/m2
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 3
- States / cities
- Newark, Delaware • Albuquerque, New Mexico • The Bronx, New York
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Digoxin, Sulfasalazine, Cooperstown Cocktail
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 102 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2015
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Chemotherapy-induced Nausea and Vomiting (CINV)
- Interventions
- Netupitant, Palonosetron
- Drug
- Lead sponsor
- Helsinn Healthcare SA
- Industry
- Eligibility
- Up to 17 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 5
- States / cities
- Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- casopitant, dolasetron, granisetron, rosiglitazone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Evansville, Indiana
- Conditions
- Brain Cancer
- Interventions
- Palonosetron (Aloxi) and Dexamethasone
- Drug
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 63 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Nausea With Vomiting Chemotherapy-Induced
- Interventions
- Granisetron Transdermal Patch, Intravenous Dexamethasone, Ondansetron
- Drug
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 90 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- Docetaxel, Casopitant/Docetaxel
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 4
- States / cities
- Hot Springs, Arkansas • Iowa City, Iowa • Detroit, Michigan + 1 more
- Conditions
- Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- dolasetron mesylate, granisetron hydrochloride, ondansetron, tropisetron, quality-of-life assessment
- Drug · Procedure
- Lead sponsor
- Gary Morrow
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 700 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2001
- U.S. locations
- 2
- States / cities
- Hackensack, New Jersey • Rochester, New York
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Granisetron, Dexamethasone, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,369 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Sarcoma, Chemotherapy-induced Nausea and Vomiting, Effects of Chemotherapy, Adverse Effects of Medical Drugs
- Interventions
- Fosaprepitant, Dexamethasone, 5HT3 receptor antagonist, Ifosfamide-based chemotherapy (AI), Doxorubicin, Mesna, Ifosfamide, Vincristine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2016
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chemotherapy-induced Nausea and Vomiting
- Interventions
- Rolapitant, Granisetron, dexamethasone, Placebo
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 532 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 1
- States / cities
- Waltham, Massachusetts
- Conditions
- Breakthrough Nausea and Vomiting, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- fosaprepitant dimeglumine, systemic chemotherapy, survey administration, quality-of-life assessment
- Drug · Other · Procedure
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Nausea and Vomiting, Chemotherapy-Induced
- Interventions
- ondansetron, moxifloxacin, saline
- Drug · Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011
- U.S. locations
- 1
- States / cities
- Austin, Texas
- Conditions
- Chemotherapy-induced Neutropenia, Chemotherapy-induced Nausea and Vomiting, Anxiety, Depression, Fatigue, Neoplasms
- Interventions
- symptom management program for chemotherapy patients
- Behavioral
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 25 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire